We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

215 hedge funds and large institutions have $3.9B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 85 increasing their positions, 78 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more call options, than puts

Call options by funds: $95M | Put options by funds: $45.4M

9% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 78

5% less funds holding

Funds holding: 226215 (-11)

10% less capital invested

Capital invested by funds: $4.34B → $3.9B (-$442M)

19% less funds holding in top 10

Funds holding in top 10: 1613 (-3)

33% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 33

Holders
215
Holders Change
-11
Holders Change %
-4.87%
% of All Funds
4.34%
Holding in Top 10
13
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-18.75%
% of All Funds
0.26%
New
22
Increased
85
Reduced
78
Closed
33
Calls
$95M
Puts
$45.4M
Net Calls
+$49.5M
Net Calls Change
-$72.8M
Name Holding Trade Value Shares
Change
Change in
Stake
HRCM
51
Hood River Capital Management
Florida
$13.4M -$1.35M -20,662 -9%
VOYA Investment Management
52
VOYA Investment Management
Georgia
$13.4M -$133K -2,024 -1%
FCM
53
Frontier Capital Management
Massachusetts
$13M +$2.06M +31,488 +19%
EA
54
Emerald Advisers
Pennsylvania
$12.9M -$19.5M -297,267 -60%
EMFAT
55
Emerald Mutual Fund Advisers Trust
Pennsylvania
$12.1M -$16.6M -253,284 -58%
D.E. Shaw & Co
56
D.E. Shaw & Co
New York
$11.7M +$3.67M +55,957 +45%
American Century Companies
57
American Century Companies
Missouri
$11.6M +$1.82M +27,811 +19%
CS
58
Candriam SCA
Luxembourg
$10.2M -$1.04M -15,912 -9%
BAMCO Inc
59
BAMCO Inc
New York
$10M +$190K +2,900 +2%
NM
60
NWI Management
New York
$9.43M -$16.7M -255,000 -64%
Two Sigma Advisers
61
Two Sigma Advisers
New York
$9.12M +$1.55M +23,600 +20%
IBT
62
International Biotechnology Trust
United Kingdom
$8.93M +$6.06M +92,400 +205%
CM
63
Caption Management
Oklahoma
$8.65M +$5.09M +77,684 +140%
ACM
64
Atika Capital Management
New York
$8.35M -$1.11M -17,000 -12%
CM
65
Castleark Management
Illinois
$8.32M +$2.46M +37,511 +41%
GKIM
66
GW&K Investment Management
Massachusetts
$7.76M +$1.53M +23,299 +24%
State of Wisconsin Investment Board
67
State of Wisconsin Investment Board
Wisconsin
$7.53M
OM
68
Opaleye Management
Massachusetts
$7.43M
Swiss National Bank
69
Swiss National Bank
Switzerland
$7.33M +$144K +2,200 +2%
Bank of America
70
Bank of America
North Carolina
$7.22M -$76K -1,159 -1%
California Public Employees Retirement System
71
California Public Employees Retirement System
California
$7.08M +$854K +13,024 +14%
Federated Hermes
72
Federated Hermes
Pennsylvania
$6.72M +$775K +11,823 +13%
GGHC
73
Gilder Gagnon Howe & Co
New York
$6.62M -$38.1K -581 -0.6%
GCM
74
Glenview Capital Management
New York
$6.31M -$1.53M -23,285 -19%
LCG
75
Lisanti Capital Growth
New York
$6.08M +$2.52M +38,443 +70%

BHVN Hedge Fund Activity: Q3 2020 in Review

215 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2020, worth a combined $3.9B — down 10% from $4.34B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of BHVN and 22 opened new positions — a net loss of 11 holders — while 78 trimmed existing stakes and 85 added.

The largest buyer was Capital World Investors, adding an estimated $72.8M. The largest seller was Vanguard Group, cutting an estimated $29.8M.

  • 215 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2020, down from 226 in Q2 2020.
  • Funds reported $3.9B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2020, down 10% quarter-over-quarter.
  • 22 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2020 and 33 closed out, a net change of -11 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2020 was Capital World Investors, an estimated $72.8M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2020 was Vanguard Group, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2020.